Previous 10 | Next 10 |
Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio PR Newswire NEW YORK , Feb. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company , today announced that it will continue its ...
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic PR Newswire Hoth's HT-KIT has received FDA Orphan Drug Status and Continues to Show Positive Study Results in Treating Mast Cell-Derived Cancers NEW YORK , Feb....
Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024 PR Newswire NEW YORK , Feb. 13, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie , Chief Executive Of...
2024-01-18 09:57:45 ET More on Hoth Therapeutics Hoth stock jumps on positive FDA feedback on drug HT-KIT Prothena, BioVie among decliners after Biogen data for new Alzheimer’s therapy Seeking Alpha’s Quant Rating on Hoth Therapeutics Historical...
Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients PR Newswire Patients will be able to enroll in trial at any time and regardless of failure from other therapeutics NEW YORK , Jan. 18, 2024 ...
2023-12-27 10:00:36 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Healthcare and utilities could perform better in 2024 - analyst Arcus, Bristol-Myers, ...
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami PR Newswire NEW YORK , Dec. 27, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a patient-focused biopharmaceutical c...
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies PR Newswire NEW YORK , Dec. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical com...
2023-11-14 09:45:28 ET Hoth Therapeutics ( NASDAQ: HOTH ) stock jumped 6% in early trading after the company said it received positive feedback from the FDA on the proposed development plan for its oncology drug candidate HT-KIT. Hoth said in a statement that it met with the...
Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT PR Newswire Hoth intends to continue development under Orphan Drug Designation NEW YORK , Nov. 14, 2023 /PRNewswire/ -- Ho...
News, Short Squeeze, Breakout and More Instantly...
Hoth Therapeutics Inc. Company Name:
HOTH Stock Symbol:
NYSE Market:
Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024 PR Newswire NEW YORK , May 1, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie , Chief Executive Offi...
China Resources Beer (Holdings) Company Limited ADR (CRHKY) is expected to report for Q4 2023 Melco International Development Ltd. (MDEVF) is expected to report for quarter end 2023-12-31 Meridian Mining UK Societas (MRRDF) is expected to report $0 for Q4 2023 BKF Capital Group Inc (B...
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds PR Newswire NEW YORK , March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a defin...